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EDITORIAL COMMENTARYClosing in on the perfect FontanHarold M. Burkhart, MDSee related article on pages 2517-24.Since the introduction of the Fontan operation more than 4
decades ago, many modifications to the operation have
occurred and have been debated in the name of finding
the ‘‘perfect’’ Fontan. Along the way, the ‘‘Ten Command-
ments’’ for a Fontan have been reduced to 4 or 5. Valves
have been repaired, subaortic and aortic arch obstructions
have been relieved, and pulmonary architecture has been
altered, all in hopes of producing a perfect Fontan
circulation. Although progress has certainly been made
with the surgical modifications, controversy still exists.
Extracardiac or lateral tunnel, fenestration or no fenestra-
tion, beating heart or cardiac arrest, and even on-pump or
off-pump are just of few of the issues currently debated.
The one thing in common with regard to these controversies
is that excellent surgical results can be expected in the
current era.
Dabal and colleagues1 present a 2-decade review of their
experiencewith 207Fontan procedures performedwith an in-
ternal or, more recently, external polytetrafluoroethylene
conduit. The patient group was a complex group. Tricuspid
atresia and double-inlet left ventricle accounted for 42%,
whereas hypoplastic left heart syndrome accounted for only
9% because representation of these cases was limited to
the last decade of the study period. Earlymortality was excel-
lent, decreasing from 7% in the earlier era to 0% in the last 6
years of the review.With robust long-term follow-up, the sur-
vival was noted to be 77% at 20 years. Importantly and
uniquely, during this period no late phase of increasing risk
was identified. Furthermore, freedom from any reoperation,
including transplant, was greater than 90% at 20 years. Dabal
and colleagues1 should be congratulated on their surgical
results in constructing a ‘‘perfect’’ Fontan pathway that has
provided excellent palliation in the first 1 to 2 decades.
One area in which the review falls short is in the
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that likely several surgeons have been involved, this is a
formidable request. As we look to closing in on the perfect
Fontan pathway, however, it would be helpful to know how
much atrioventricular regurgitation is too much, what ven-
tricular function is good enough, and just how small the pul-
monary arteries can be. Although these issues affect all
Fontan candidates, they are no more readily apparent than
in the patients with hypoplastic left heart syndrome. In a
time when the expectation from medical colleagues and
families is to progress to a Fontan operation, further studies
from this group as well as others need to focus on defining
these exclusion criteria.
Finally, it bears keeping in mind that the story with a
perfect Fontan pathway does not end at 20 years. Clearly,
the Fontan reconstruction has given palliation and sur-
vival to a complex group of patients who, before the
operation, had few options. It is important to remember
the spirit in which the operation was developed and in-
tended. At 20 and 30 years after the Fontan operation,
we are becoming increasingly aware of the drawbacks
of this approach. Elevated central venous pressure and
lower cardiac output do not appear to be tolerated for a
long period in many patients, with liver disease and
protein-losing enteropathy becoming more prevalent.
Although a perfect Fontan pathway is a key step to the
care of these difficult patients, it is just part of the ulti-
mate solution. Certainly patient selection is critical,
with some better served with a pulsatile Glenn shunt.
For those who do go on to Fontan operation, research
focusing on stem cell therapy, mechanical assist devices,
and medical therapy such as pulmonary dilators may pro-
vide the next step.Reference
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